MS BioNTech WKN: A2PSR2 ISIN: US09075V1026 Kürzel: BNTX Forum: Aktien User: Thekla

Moderna announces Phase 3 trial of mRNA-1283 met primary efficacy endpoint Moderna announced that its Phase 3 trial of mRNA-1283, an investigational next-generation COVID-19 vaccine, has met its primary efficacy endpoint, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax. The Company also announced that higher efficacy was observed in adults 18 years of age and older compared to Spikevax, with a consistent trend observed in the subset of adults age 65 and older. Positive interim immunogenicity results for mRNA-1283 in this study were previously reported in March 2024. The ongoing Phase 3 clinical trial is a randomized, observer-blind, active-controlled study of approximately 11,400 individuals aged 12 years and older. Half of the participants received a 10 undefined dose of mRNA-1283, while the other half received a 50 undefined dose of mRNA-1273. Today's vaccine efficacy data are consistent with the previously announced immunogenicity results from the study, which showed that mRNA-1283 had higher neutralizing antibody responses against both Omicron BA.4/5 and ancestral SARS-CoV-2 than mRNA-1273, with the highest geometric mean titer ratios observed in adults and in the subset of participants aged 65 years and older. In the trial, mRNA-1283 was found to have a similar safety profile to Spikevax. The most commonly solicited side effects were injection site pain, fatigue, headache and myalgia. Moderna's combination vaccine candidate against influenza and COVID-19, mRNA-1083, includes mRNA-1283. That vaccine candidate recently announced positive results in its separate Phase 3 trial. Moderna plans to present the Phase 3 clinical data for mRNA-1283 at an upcoming conference as well as submit it for publication. The Company will also engage with regulators on the next steps for the program.

Dafür gibts Meldungen von Moderna: Der COVID-Impfstoff der nächsten Generation von Moderna zeigt keine Unterlegenheit gegenüber der aktuellen Impfung 13. Juni 202413:16 MESZ https://de.tradingview.com/news/reuters.com,2024:newsml_L8N3IB0TR:0/

Dabei fängt der Sommer gerade erst an 🤔 🌞

Die PR-Abteilung von Biontech scheint komplett im Sommerurlaub zu sein 😎 Momentan ist absolute "tote Hose" - daher aktuell auch nur 10 Nutzer aktiv und der Kurs im Sinkflug😅. Hoffe es kommen bald mal wieder positive Nachrichten 🙏

Guten Morgen

Der Börsentag (NTV) Start 🌏 https://www.n-tv.de/25010498

🌏 Guten Morgen allerseits 🍏🍀🥂 🌊🚢🚢🌊🌞

Moin - Tesla reißt uns mit nach oben… ⬆️ 😅

Moin 🙋‍♂️☕️zusammen

📌12.06. 🔔9️⃣0️⃣,6️⃣2️⃣ Last Trade: $97.91 Day's High: $101.87 Day's Low: $97.51 Previous Close: $98.80 Change: -0.90% Volume: 510,797

Guten Morgen, ☕️🍳🥨 MS BioNTech ⛴️🌊📕✍️🏼👮🏼‍♀️ Logbuch 2024 13.06. Kurs: 9️⃣1️⃣,9️⃣8️⃣📉9️⃣0️⃣,6️⃣2️⃣ Termine:⬆️⬆️⬆️ keine Fed Termine keine PK Powell keine Inflationdaten es wird relativ ruhig heute, Zeit zum Planen Aufräumen Umschichten in der Kleiderkammer es wird heiß 🔥 nächste Woche Uffbasse 🌍🕊🌬🌊⛴️  🌊    ☘️☘️☘️☘️ Volle Kraft voraus.      Schiff Ahoi                 ✍️🏼Eure Thekla 👮🏼‍♀️⛴️👋

📌Termine 🔸️EUR 11:00 : Industrieproduktion 4/24 🔸️DEU 12:00 : IWH-Konjunkturprognose zum Sommer 2024 🔸️USA ▪️14:30 Erstanträge ▪️Arbeitslosenhilfe (Woche) ▪️Erzeugerpreise 5/24 ▪️22:30 TeslHauptversammlung https://www.boersennews.de/nachrichten/artikel/tagesvorschau--termine-am-13--juni-2024/4472046/?utm_source=BoersennewsShare&utm_medium=App&utm_campaign=News

Guten Morgen zusammen. Auf gehts BioNTech 🍀🍀🍀

Markus Koch Closing Bell https://www.youtube.com/live/5PrO5saAjNE?si=qgZkx_PYlMDQJNdE

Und weiterhin Geduld...🤔